For the quarter ending 2026-03-31, LYEL made $2K in revenue. -$24,404K in net income. Net profit margin of -1220200.00%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 2 | 6 | 15 | 8 |
| Research and development | 36,604 | 102,670* | 28,172 | 34,857 |
| General and administrative | 9,555 | 10,616 | 10,687 | 9,786 |
| Other operating income, net | 1,896 | 1,497 | 1,591 | -1,062 |
| Acquired in-process research and development | - | 16,583* | - | - |
| Impairment of long-lived assets | - | -721* | 0 | 1,443 |
| Total operating expenses | 44,263 | 127,650 | 37,268 | 47,148 |
| Loss from operations | -44,261 | -127,644 | -37,253 | -47,140 |
| Interest income, net | 2,194 | 2,676 | 3,266 | 3,276 |
| Other income, net | 17,914 | -15,755 | -4,859 | 1,180 |
| Impairment of other investments | - | 0 | 0 | 0 |
| Total other income, net | 20,108 | -13,079 | -1,593 | 4,456 |
| Net loss | -24,153 | -140,723 | -38,846 | -42,684 |
| Net unrealized gain on marketable securities | -251 | 41 | 144 | -101 |
| Comprehensive loss | -24,404 | -140,682 | -38,702 | -42,785 |
| Basic EPS | -1.1 | -8.23 | -2.13 | -2.89 |
| Diluted EPS | -1.1 | -8.23 | -2.13 | -2.89 |
| Basic Average Shares | 21,876,000 | 17,093,000* | 18,268,000 | 14,793,000 |
| Diluted Average Shares | 21,876,000 | 17,093,000* | 18,268,000 | 14,793,000 |
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)